[1] VANKA K S, SHUKLA S, GOMEZ H M, et al.Understanding the pathogenesis of occupational coal and silica dust-associated lung disease[J].Eur Respir Rev, 2022, 31(165):210250.
[2] KREFFT S, WOLFF J, ROSE C.Silicosis:an update and guide for clinicians[J].Clin Chest Med, 2020, 41(4):709-722.
[3] 毛翎, 彭莉君, 王焕强.尘肺病治疗中国专家共识(2018年版)[J].环境与职业医学, 2018, 35(8):677-689.
[4] HANDRA C M, GURZU I L, CHIRILA M, et al.Silicosis:new challenges from an old inflammatory and fibrotic disease[J].Front Biosci (Landmark Ed), 2023, 28(5):96.
[5] Artificial stone silicosis:rapid progression following exposure cessation[J].Chest, 2020, 158(3):1060-1068.
[6] 杨秋月, 王海椒, 刘丽华, 等.2002-2016年中国接触矽尘人群矽肺患病率的Meta分析[J].中国工业医学杂志, 2018, 31(4):307-308.
[7] CHEN S, LIU M, XIE F.Global and national burden and trends of mortality and disability-adjusted life years for silicosis, from 1990 to 2019:results from the global burden of disease study 2019[J].BMC Pulm Med, 2022, 22(1):240.
[8] NING H, ZHOU Y, ZHOU Z, et al.Challenges to improving occupational health in China[J].Occup Environ Med, 2017, 74(12):924-925.
[9] 朱晓俊, 肖培, 王丹, 等.1990年至2017年中国人群尘肺病的疾病负担分析[J].中国工业医学杂志, 2019, 32(5):341-346.
[10] 张曌慧, 黄磊, 石璐, 等.中国人群尘肺病疾病负担的系统评价[J].中国循证医学杂志, 2021, 21(3):276-283.
[11] WEI J, ZHAO Q, YANG G, et al.Mesenchymal stem cells ameliorate silica-induced pulmonary fibrosis by inhibition of inflammation and epithelial-mesenchymal transition[J].J Cell Mol Med, 2021, 25(13):6417-6428.
[12] GREENBERG M I, WAKSMAN J, CURTIS J.Silicosis:a review[J].Dis Mon, 2007, 53(8):394-416.
[13] LI R, KANG H, CHEN S.From basic research to clinical practice:considerations for treatment drugs for silicosis[J].Int J Mol Sci, 2023, 24(9):8333.
[14] ADAMCAKOVA J, MOKRA D.New insights into pathomechanisms and treatment possibilities for lung silicosis[J].Int J Mol Sci, 2021, 22(8):4162.
[15] XIE Y, MA J, YANG M, et al.Extracellular signal-regulated kinase signaling pathway and silicosis[J].Toxicol Res (Camb), 2021, 10(3):487-494.
[16] YANO T, YANO Y, NAGASHIMA Y, et al.Activation of extracellular signal-regulated kinase in lung tissues of mice treated with carcinogen[J].Life Sci, 1999, 64(4):229-236.
[17] NAKASHIMA K, SATO T, SHIGEMORI S, et al.Regulatory role of heme oxygenase-1 in silica-induced lung injury[J].Respir Res, 2018, 19(1):144.
[18] FAN Y, ZHENG C, WV N, et al.Telomerase gene variants and telomere shortening in patients with silicosis or asbestosis[J].Occup Environ Med, 2020:oemed-2020-107046.
[19] STOCK C J W, RENZONI E A.Telomeres in interstitial lung disease[J].J Clin Med, 2021, 10(7):1384.
[20] YIN H, XIE Y, GU P, et al.The emerging role of epigenetic regulation in the progression of silicosis[J].Clin Epigenetics, 2022, 14(1):169.
[21] VELAGACHERLA V, MEHTA C H, NAYAK Y, et al.Molecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis[J].Life Sci, 2022, 291:120283.
[22] ZHAO H, WANG Y, QIU T, et al.Autophagy, an important therapeutic target for pulmonary fibrosis diseases[J].Clin Chim Acta, 2020, 502:139-147.
[23] POLLARD K M.Silica, silicosis, and autoimmunity[J].Front Immunol, 2016, 7:97.
[24] ZHAO Y, HAO C, LI M, et al.PD-1/PD-L1 inhibitor ameliorates silica-induced pulmonary fibrosis by maintaining systemic immune homeostasis[J].Biomed Pharmacother, 2022, 148:112768.
[25] LEE S, MATSUZAKI H, KUMAGAI-TAKEI N, et al.Silica exposure and altered regulation of autoimmunity[J].Environ Health Prev Med, 2014, 19(5):322-329.
[26] HOY R F, GLASS D C, DIMITRIADIS C, et al.Identification of early-stage silicosis through health screening of stone benchtop industry workers in Victoria, Australia[J].Occup Environ Med, 2021, 78(4):296-302.
[27] FERNÁNDEZ ÁLVAREZ R, MARTÍNEZ GONZÁLEZ C, QUERO MARTÍNEZ A, et al.Guidelines for the diagnosis and monitoring of silicosis.[J].Arch Bronconeumol, 2015, 51(2):86-93.
[28] AUSTIN E K, JAMES C, TESSIER J.Early detection methods for silicosis in Australia and internationally:a review of the literature[J].Int J Environ Res Public Health, 2021, 18(15):8123.
[29] NEWBIGIN K, PARSON R, DELLER D, et al.Stonemasons with silicosis:preliminary findings and a warning message from Australia[J].Respirology, 2019, 24(12):1220-1221.
[30] EXPERT PANEL ON THORACIC IMAGING, BACCHVS L, SHAH R D, et al.ACR appropriateness criteria review ACR Appropriateness Criteria® occupational lung diseases[J].J Thorac Imaging, 2016, 31(1):W1-W3.
[31] BLANCO-PÉREZ J J, BLANCO-DORADO S, RODRÍGUEZ-GARCÍA J, et al.Serum levels of inflammatory mediators as prognostic biomarker in silica exposed workers[J].Sci Rep, 2021, 11(1):13348.
[32] HUANG H-B, HUANG J-L, XU X-T, et al.Serum neuron-specific enolase:a promising biomarker of silicosis[J].World J Clin Cases, 2021, 9(5):1016-1025.
[33] NANDI S S, LAMBE U P, SARKAR K, et al.A rapid point of care CC16 kit for screening of occupational silica dust exposed workers for early detection of silicosis/silico-tuberculosis[J].Sci Rep, 2021, 11(1):23485.
[34] LEESE E, STAFF J F, CAROLAN V A, et al.Exhaled breath condensate:a novel matrix for biological monitoring to assess occupational exposure to respirable crystalline silica[J].Ann Work Expo Health, 2017, 61(7):902-906.
[35] SHEN J, FENG J, WU Z, et al.Apelin prevents and alleviates crystalline silica-induced pulmonary fibrosis via inhibiting transforming growth factor beta 1-triggered fibroblast activation[J].Int J Biol Sci, 2023, 19(13):4004-4019.
[36] 李玉洁, 贾晓民.矽肺的治疗进展[J].临床肺科杂志, 2017, 22(6):1119-1122.
[37] SONG M Y, WANG J X, SUN Y L, et al.Tetrandrine alleviates silicosis by inhibiting canonical and non-canonical NLRP3 inflammasome activation in lung macrophages[J].Acta Pharmacol Sin, 2022, 43(5):1274-1284.
[38] 侯博文, 李宝平, 孙治平, 等.汉防己甲素片联合大容量全肺灌洗术治疗尘肺的临床效果[J].职业与健康, 2020, 36(16):2164-2167.
[39] 晏丽, 彭莹, 贺炜, 等.大剂量乙酰半胱氨酸联合汉防己甲素治疗尘肺病的随机对照临床试验[J].职业卫生与应急救援, 2021, 39(5):524-528.
[40] ZHANG H, CHEN S, ZENG M, et al.Apelin-13 administration protects against LPS-induced acute lung injury by inhibiting NF-κB pathway and NLRP3 inflammasome activation[J].Cell Physiol Biochem, 2018, 49(5):1918-1932.
[41] TANG Q, XING C, LI M, et al.Pirfenidone ameliorates pulmonary inflammation and fibrosis in a rat silicosis model by inhibiting macrophage polarization and JAK2/STAT3 signaling pathways[J].Ecotoxicol Environ Saf, 2022, 244:114066.
[42] CAO I J, LIU Y, ZHANG Z, et al.Pirfenidone ameliorates silica-induced lung inflammation and fibrosis in mice by inhibiting the secretion of interleukin-17A[J].Acta Pharmacol Sin, 2022, 43(4):908-918.
[43] ANDRADE DA SILVA L H, VIEIRA J B, CABRAL M R, et al.Development of nintedanib nanosuspension for inhaled treatment of experimental silicosis[J].Bioeng Transl Med, 2022, 8(2):e10401.
[44] PANG X, SHAO L, NIE X, et al.Emodin attenuates silica-induced lung injury by inhibition of inflammation, apoptosis and epithelial-mesenchymal transition[J].Int Immunopharmacol, 2021, 91:107277.
[45] ZHANG N, LIU K, WANG K, et al.Dust induces lung fibrosis through dysregulated DNA methylation[J].Environ Toxicol, 2019, 34(6):728-741.
[46] GAO X, XU H, XU D, et al.MiR-411-3p alleviates Silica-induced pulmonary fibrosis by regulating Smurf2/TGF-β signaling[J].Exp Cell Res, 2020, 388(2):111878.
[47] XIONG W, LIU Z G, XIONG L, et al.CD3+, CD4+, and CD8+expression in cells in peripheral blood of silicosis patients and intervention effect of thymalfasin[J].Ann Clin Lab Sci, 2019, 49(3):368-371.
[48] ZHANG Y, ZHENG J.Functions of immune checkpoint molecules beyond immune evasion[J].Adv Exp Med Biol, 2020:201-226.
[49] ZHAO Y, QU Y, DUAN M, et al.Dynamics of the inhibitory immune checkpoint TIM-3 in mouse pulmonary phagocytes after silica exposure[J].Ecotoxicol Environ Saf, 2023, 261:115087.
[50] TIAN X, WEI Y, HOU R, et al.Yangqing Chenfei formula alleviates silica-induced pulmonary inflammation in rats by inhibiting macrophage M1 polarization[J].Chin Med, 2023, 18:79.
[51] LI T, YANG X, XU H, et al.Early identification, accurate diagnosis, and treatment of silicosis[J].Can Respir J, 2022, 2022:3769134.
[52] 孙治平, 李宝平, 高丽妮, 等.尘肺病患者双肺大容量肺灌洗治疗前后生存质量对比分析[J].职业与健康, 2021, 37(13):1834-1836, 1839.
[53] CHAMBERS D C, APTE S H, DELLER D, et al.Radiological outcomes of whole lung lavage for artificial stone-associated silicosis[J].Respirology, 2021, 26(5):501-503.
[54] 倪旭青, 赵章凡, 张竞雄, 等.两种纤维镜支气管肺灌洗方法治疗矽肺患者的临床观察[J].工业卫生与职业病, 2019, 45(2):134-137.
[55] 王娟.珐菲亚参胶囊辅助大容量全肺灌洗术治疗煤工尘肺的临床效果观察[J].现代医学, 2016, 44(2):239-241.
[56] JU C, YANG Y, LIAN Q, et al.Clinical outcomes and survival following lung transplantation for work-related lung disease:a single-center retrospective cohort study[J].J Occup Med Toxicol, 2023, 18(1):1-7.
[57] CHAMBERS D C, CHERIKH W S, HARHAY M O, et al.The international thoracic organ transplant registry of the international society for heart and lung transplantation:thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme:donor and recipient size match[J].J Heart Lung Transplant, 2019, 38(10):1042-1055.
[58] SIDNEY-FILHO L A, WATTE G, DOS SANTOS P A R, et al.What is expected in lung function after lung transplantation due to end-stage pulmonary silicosis?[J].Clin Transplant, 2017, 31(11):e13105.
[59] 毛文君, 陈静瑜, 郑明峰, 等.肺移植治疗Ⅲ期矽肺32例临床分析[J].中华外科杂志, 2016, 54(12):902-907.
[60] 毛文君, 聂晓伟, 夏维, 等.肺移植治疗Ⅲ期矽肺术后生存的影响因素[J].中华劳动卫生职业病杂志, 2016, 34(9):659-664.
[61] HAYES D, HAYES K T, HAYES H C, et al.Long-term survival after lung transplantation in patients with silicosis and other occupational lung disease[J].Lung, 2015, 193(6):927-931.
[62] 盛玲, 仇胜利, 陈静瑜.8例不横断胸骨前胸外侧小切口序贯双肺移植手术配合体会[J].现代医学, 2022, 50(11):1431-1434.
[63] BLACKLEY D J, HALLDIN C N, HAYANGA J W A, et al.Transplantation for work-related lung disease in the USA[J].Occup Environ Med, 2020, 77(11):790-794.
[64] GREWAL H S, THANIYAVARN T, ARCASOY S M, et al.Common noninfectious complications following lung transplantation[J].Clin Chest Med, 2023, 44(1):179-190.
[65] 马煜, 瞿介明, 左为.呼吸系统干细胞临床研究进展[J].中国细胞生物学学报, 2018, 40(S1):2216-2225.
[66] 陈尚雅, 辛晓丽, 杜忠君, 等.间充质干细胞治疗实验性矽肺的研究进展[J].中华劳动卫生职业病杂志, 2017, 35(7):553-556.
[67] MELO M M, CRVZ F F, ROCCO P R M.Mesenchymal stromal cell therapy for chronic lung diseases:experimental and clinical evidence[J].Expert Rev Respir Med, 2023, 17(3):223-235.
[68] LI D Y, LI R F, SUN D X, et al.Mesenchymal stem cell therapy in pulmonary fibrosis:a meta-analysis of preclinical studies[J].Stem Cell Res Ther, 2021, 12(1):461.
[69] ZHAO R, SU Z, WU J, et al.Serious adverse events of cell therapy for respiratory diseases:a systematic review and meta-analysis[J].Oncotarget, 2017, 8(18):30511-30523.
[70] LIU W W, WANG H X, YU W, et al.Treatment of silicosis with hepatocyte growth factor-modified autologous bone marrow stromal cells:a non-randomized study with follow-up[J].Genet Mol Res, 2015, 14(3):10672-10681.
[71] MORALES M M, SOUZA S A L, LOIVOS L P, et al.Pilot safety study of intrabronchial instillation of bone marrow-derived mononuclear cells in patients with silicosis[J].BMC Pulm Med, 2015, 15:66.
[72] SHAO H, IM H, CASTRO C M, et al.New technologies for analysis of extracellular vesicles[J].Chem Rev, 2018, 118(4):1917-1950.
[73] VU L T, GONG J, PHAM T T, et al.MicroRNA exchange via extracellular vesicles in cancer[J].Cell Prolif, 2020, 53(11):e12877.
[74] HERRMANN I K, WOOD M J A, FUHRMANN G.Extracellular vesicles as a next-generation drug delivery platform[J].Nat Nanotechnol, 2021, 16(7):748-759.
[75] GUO H, SU Y, DENG F.Effects of mesenchymal stromal cell-derived extracellular vesicles in lung diseases:current status and future perspectives[J].Stem Cell Rev Rep, 2021, 17(2):440-458.
[76] MATSUZAKA Y, YASHIRO R.Therapeutic strategy of mesenchymal-stem-cell-derived extracellular vesicles as regenerative medicine[J].Int J Mol Sci, 2022, 23(12):6480.
[77] CRUZ F F, ROCCO P R M.The potential of mesenchymal stem cell therapy for chronic lung disease[J].Expert Rev Respir Med, 2020, 14(1):31-39.
[78] THANUNCHAI M, HONGENG S, THITITHANYANONT A.Mesenchymal stromal cells and viral infection[J].Stem Cells Int, 2015, 2015:860950.
[79] COPPIN L, SOKAL E, STÉPHENNE X.Thrombogenic risk induced by intravascular mesenchymal stem cell therapy:current status and future perspectives[J].Cells, 2019, 8(10):1160.
[80] WANG Y, TANG N.The diversity of adult lung epithelial stem cells and their niche in homeostasis and regeneration[J].Sci China Life Sci, 2021, 64(12):2045-2059. |
